<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Characteristics of type 1 and type 2 diabetes mellitus in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Characteristics of type 1 and type 2 diabetes mellitus in children and adolescents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Characteristics of type 1 and type 2 diabetes mellitus in children and adolescents</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Type 1 diabetes</td> <td class="subtitle1">Type 2 diabetes</td> </tr> <tr> <td><strong>Prevalence</strong></td> <td>Common, increasing</td> <td>Increasing</td> </tr> <tr> <td><strong>Age at presentation</strong></td> <td>Throughout childhood</td> <td>Puberty</td> </tr> <tr> <td><strong>Onset</strong></td> <td>Typically acute severe</td> <td>Insidious to severe</td> </tr> <tr> <td><strong>Ketosis at onset</strong></td> <td>Common</td> <td>5 to 10%*</td> </tr> <tr> <td><strong>Affected relative</strong></td> <td>5 to 10%</td> <td>75 to 90%</td> </tr> <tr> <td><strong>Female:male</strong></td> <td>1:1</td> <td>Approximately 2:1</td> </tr> <tr> <td><strong>Inheritance</strong></td> <td>Polygenic</td> <td>Polygenic</td> </tr> <tr> <td><strong>HLA-DR3/4</strong></td> <td>Strong association</td> <td>No association</td> </tr> <tr> <td><strong>Ethnicity</strong></td> <td>Most common in non-Hispanic White people</td> <td>All<sup>¶</sup></td> </tr> <tr> <td><strong>Insulin secretion</strong></td> <td>Decreased/absent</td> <td>Variable</td> </tr> <tr> <td><strong>Insulin sensitivity</strong></td> <td>Normal when controlled</td> <td>Decreased</td> </tr> <tr> <td><strong>Insulin dependence</strong></td> <td>Permanent</td> <td>Variable</td> </tr> <tr> <td><strong>Obese or overweight</strong></td> <td>20 to 25% overweight<sup>Δ</sup></td> <td>&gt;80% obese</td> </tr> <tr> <td><strong>Acanthosis nigricans</strong></td> <td>12%<sup>◊</sup></td> <td>50 to 90%<sup>◊</sup></td> </tr> <tr> <td><strong>Pancreatic antibodies</strong></td> <td>Yes<sup>§</sup></td> <td>No<sup>¥</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; IAA: autoantibodies to insulin; ICA: islet cell cytoplasm; GAD: glutamic acid decarboxylase; IA: tyrosine phosphatase (insulinoma-associated) antibody; ZnT8: zinc channel antibody.<br/>* Reported frequency of ketonuria or ketoacidosis at time of diagnosis of T2DM varies widely.<br/>¶ In North America, T2DM predominates in Native American, African American, Hispanic, Canadian First Nation, Pacific Islander, and Asian American youth<sup innerhtml="">[1]</sup>.<br/>Δ With increased prevalence of childhood overweight, 20 to 25% of newly diagnosed children with T1DM are overweight, which is higher than the prevalence of <em>overweight </em>in a similar population without T1DM. However, the prevalence of <em>obesity</em> is not increased among children and adolescents with T1DM<sup innerhtml="">[2,3]</sup>. Recent weight loss is common at presentation of children with T1DM, including among those who are overweight or obese. <br/><font class="lozenge">◊</font> These frequencies of acanthosis nigricans are based on a registry study in the United States. Populations with lower rates of obesity or different ethnic mixes may have different results<sup>[</sup><sup innerhtml="">4]</sup>.<br/>§ IAA, ICA, GAD, IA-2 and IA-2-beta, or ZnT8 are present at diagnosis in 85 to 98% of patients with T1DM<sup>[</sup><sup innerhtml="">4,5]</sup>.<br/>¥ One study reported that 9.8% of youth with phenotypic T2DM have pancreatic antibodies to IA-2 and/or GAD<sup innerhtml="">[6]</sup>.</div><div class="graphic_reference">References:

<ol>
<li>Mayer-Davis EJ, Bell RA, Dabelea D, et al. The many faces of diabetes in American youth: type 1 and type 2 diabetes in five race and ethnic populations: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S99.</li>
<li>Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.</li>
<li>Kaminski BM, Klingensmith GJ, Beck RW, et al. Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr 2013; 162:736.</li>
<li>Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.</li>
<li>Steck AK, Johnson K, Barriga KJ. Age of Islet Autoantibody Appearance and Mean Levels of Insulin, but Not GAD or IA-2 Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes. Diabetes Care 2011; 34:1397.</li>
<li>Klingensmith GJ, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.</li>
</ol>

Modified from: Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes care 1999; 22:345-354.</div><div id="graphicVersion">Graphic 59370 Version 20.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
